Is Gout Hereditary? What ABCG2, SLC2A9 and 2.6 Million People Actually Show

Is Gout Hereditary? What ABCG2, SLC2A9 and 2.6 Million People Actually Show

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Gout is not one failure but two, and both are partly inherited. The first is how the body clears urate, which is governed by transporter genes such as ABCG2 and SLC2A9. The second is how violently the immune system reacts once urate crystals form. In 2024, a genome-wide study analysed 2.6 million people, including 120,295 with gout. It reported 377 loci, meaning places on the genome linked to a trait, and 410 independent signals. Its gene-prioritisation work pointed at the inflammatory side of the disease, including regulation of the NLRP3 inflammasome. Diet matters, but only a little. A meta-analysis of five US cohorts, covering 16,760 adults of European ancestry, found diet scores explained no more than 0.3 percent of variation in serum urate. Common genetic variation explained 23.9 percent. A consumer gout likelihood is a population estimate, not a diagnosis.

What you’ll learn

• Why about one in five US adults has a high urate level while only about 4 in 100 have gout
• What the ABCG2 Q141K variant and SLC2A9 actually do, and how big their effects really are
• What the 2024 genome-wide study added, and why its clonal-hematopoiesis finding carries no clinical action yet
• Which drugs are approved in the US and Canada, with regulator names and dates, and which are not

Two locks, not one: why high uric acid is necessary for gout but nowhere near enough

Most pages about gout describe one process. Uric acid builds up, crystals form, the toe hurts. That model is incomplete, and the gap matters.

Gout is a type of arthritis that causes pain and swelling in joints. It usually comes as flares that last a week or two. Urate builds up because the body makes too much, or fails to clear enough.

Lock one: how the body gets rid of urate

About 70 percent of daily urate disposal happens through the kidneys. The other main route out is the gut, where the ABCG2 protein helps release urate for elimination. Both routes run on transporter proteins, and the genes for them vary from person to person.

Think of it as household drainage. One large pipe and one smaller pipe carry the same waste. Narrow either one and the level in the sink rises.

Lock two: what an attack actually is

A high level alone does not produce a 3 a.m. toe. Crystals must form, and the immune system must react to them.

In 2006, lab work published in Nature showed how. Urate crystals switch on a protein complex called the NALP3 inflammasome, now usually written NLRP3. That triggers release of interleukin-1 beta, a signal that calls in immune cells. Mice lacking parts of that complex could not mount the response. Mice lacking the interleukin-1 receptor showed a weaker rush of white blood cells.

The gap between the two locks, in numbers

The national US survey data make the gap concrete. In NHANES 2015-2016, gout affected 3.9 percent of US adults, about 9.2 million people. Hyperuricemia, meaning a high urate level in the blood, ran at 20.2 percent in men and 20.0 percent in women.

Two honest figures sit alongside that snapshot, and both belong here:

• Cross-sectional: about 20 in 100 US adults carry a high urate level at a given moment, while about 4 in 100 have gout.
• Lifetime conversion: the NIH gene guide states that about one-quarter of people with hyperuricemia go on to develop gout. It adds that it is unclear why the others do not.

A snapshot is not a lifetime, so these two measure different things. Both point the same way. A high urate level raises risk, and most people who carry one never develop gout.

The best stratified numbers come from an older cohort. The Normative Aging Study followed 2,046 healthy men for 14.9 years. At a urate of 9 mg/dL or more, 4.9 percent had a first gout attack each year. The figure was 0.5 percent at 7.0 to 8.9 mg/dL, and 0.1 percent below 7.0.

Even in the top group, 22 percent had an attack within five years. In plain terms, about 78 of every 100 of those men did not.

That cohort was male-only, healthy at the start, and published in 1987. It is still the clearest set of figures by urate level. It is not a modern, mixed-sex one.

This buys a better question for the next visit. Ask a primary care doctor which lock is driving the problem. Long-term drugs work on lock one. Flare drugs work on lock two.

Section recap: Gout requires both a high urate level and an inflammatory reaction to crystals. About 20 in 100 US adults have hyperuricemia while about 4 in 100 have gout, so the first lock alone is not enough.

ABCG2 and SLC2A9: what a consumer gout report is actually measuring

A consumer report that says “higher likelihood of gout” is built from many small effects. Two genes carry more weight than the rest, and both are transporters.

ABCG2 and the Q141K variant

In 2009, researchers named ABCG2 as a urate efflux transporter. They found the protein in the lining of kidney tubules, where it pushes urate out into the urine. A separate NIH page notes that the same protein also helps release urate into the gut. Those are two jobs, described by two sources, and both are real.

The common variant is Q141K, tagged by the marker rs2231142. Making that change in the lab cut urate transport by 53 percent.

An odds ratio compares two groups, and 1.00 means no change at all. A risk allele is the version of a gene that is linked to higher risk. In a study of 14,783 people, each copy of the risk allele carried an odds ratio for gout of 1.68. That means the odds were 68 percent higher per copy. The authors put at least 10 percent of gout cases in white people down to this variant.

A later meta-analysis pooled 52,010 people. A 95 percent confidence interval is the range in which the true value most likely sits. That meta-analysis reported an overall odds ratio of 1.73 per risk allele, with a 95 percent confidence interval of 1.55 to 1.91.

Group in the meta-analysis	Odds ratio per allele	95% confidence interval
All people pooled	1.73	1.55 to 1.91
Caucasian	1.68	1.50 to 1.87
Asian	1.93	1.54 to 2.31
African	1.76	1.15 to 2.36
New Zealand Pacific Islanders	2.94	1.72 to 4.15
New Zealand Maori	1.12	0.57 to 1.67 (P = 0.061, not significant)

That last row matters. In New Zealand Maori people, the same variant showed no clear link. A variant is not a switch that works the same way in everyone.

Now translate the headline number. About 3.9 in 100 US adults have gout. Multiplying that by an odds ratio of 1.73 lands near 7 in 100. That is a real increase, and it still leaves a large majority who never develop gout. The math is an illustration, not a personal forecast. Treat the exact figure with care.

SLC2A9 and the sex difference

SLC2A9 codes for a transporter that handles urate in the kidney. Variants in it explained 1.7 to 5.3 percent of the spread in serum uric acid in the first cohort. The protein was already known to carry fructose, and the same work showed it carries urate too.

A companion study found the strongest signals inside SLC2A9. Each copy of the minor allele shifted serum uric acid by about -0.23 to -0.36 mg/dL. The share of the spread it explained differed by sex. It was about 1.2 percent in men and about 6 percent in women.

That sex difference matters. The NIH arthritis institute lists menopause among gout risk factors. Being male, older age and family history are on the same list. Only a doctor can sort a swollen joint in a woman from its other causes.

What the consumer report is, in the company’s own words

The 23andMe Gout report sits under the label “Powered by 23andMe Research”. It is not one of that company’s FDA-authorised Genetic Health Risk reports. The model is built on more than 21,000 variants.

The company’s own wording is blunt. Its reports are “not intended to tell a person anything about his or her current state of health, or to be used to make medical decisions”. It also states that the service “is not intended to diagnose any disease”.

One more limit applies to every polygenic estimate. Polygenic means many genes each add a small amount, rather than one gene deciding the outcome. Scores sold today are several times more accurate in people of European ancestry than in others, and the reason is simply who has been studied. A reader of African, South Asian, East Asian, Hispanic or Indigenous ancestry should treat the percentage as less reliable. That is a gap in the data, not a claim about biology.

Bring the report to a primary care physician rather than acting on it alone.

Section recap: ABCG2 Q141K roughly halves urate transport in the lab and raises gout odds by about 1.73 per copy, while SLC2A9 matters more in women. The consumer gout report is a research-grade estimate, not a diagnosis.

The 2024 study that moved gout from a plumbing problem to an inflammation problem

Until recently, gout genetics was mostly a story about urate levels. A study in Nature Genetics in November 2024 changed that.

The scale

The authors describe “a genome-wide association study (GWAS) of 2.6 million people, including 120,295 people with prevalent gout”. They detected “377 loci and 410 genetically independent signals (149 previously unreported loci in urate and gout)”. A further 65 loci showed signals in urate but not gout. Those came from a separate study of 630,117 people.

Numbers that large are hard to picture. Imagine an orchestra of several hundred players. No single instrument carries the piece, and removing one changes very little.

The finding that reframes the disease

What the counts mean matters more than the counts. A ranking scheme picked out genes in the inflammatory side of gout. Those genes covered three areas:

• Epigenetic remodeling, meaning changes in how genes are switched on and off without altering the DNA sequence
• Cell osmolarity, meaning the balance of water and dissolved particles inside cells
• Regulation of NLRP3 inflammasome activity, the same crystal-sensing machinery found in lab work in 2006

In short, inherited variation does not only set how much urate a person carries. It also seems to shape how hard the immune system hits back at the crystals. That answers a common family puzzle. Several relatives have high urate, yet only some of them get attacks.

The clonal hematopoiesis result, with its limits stated

The study also reported that “Mendelian randomization analysis provided evidence for a causal role of clonal hematopoiesis of indeterminate potential in gout”.

Clonal hematopoiesis of indeterminate potential, or CHIP, is something that happens with age. Blood stem cells pick up changes over a lifetime. Now and then one group of them grows and makes a large share of the blood cells.

Three cautions belong with that finding:

• CHIP is acquired during life, not inherited from a parent
• Mendelian randomization is a statistics method for testing cause and effect, not a clinical trial
• The authors call the ranked genes “suitable for follow-up studies”, which is research language, not advice

No CHIP test belongs in a gout work-up today on the strength of this result. A joint specialist or family doctor is the right person to ask what does belong in one.

The NIH gene guide makes the same point in plainer language. Large studies have found dozens of genes that play a role in gout.

Section recap: A 2024 analysis of 2.6 million people found 377 loci and pointed at inflammatory genes, including NLRP3 regulation. Its clonal-hematopoiesis result is a research finding with no clinical action attached.

The diet story, with numbers attached

The first thing said to a person with gout is usually about food. The evidence backs a much smaller claim than the lectures do.

The measurement that puts diet in proportion

A study in the BMJ in 2018 pooled five US groups. It covered 16,760 adults of European ancestry, 8,414 men and 8,346 women. All were over 18 and free of kidney disease and gout. None were taking urate-lowering or water pills.

Three diet scores built on healthy-eating rules went with lower serum urate. A fourth pattern went with higher urate. Each of the four explained no more than 0.3 percent of the spread in serum urate. Common genetic variation explained 23.9 percent. The authors concluded that “diet explains very little variation in serum urate levels in the general population”.

That is a gap of about a hundredfold. A person who quit beer and flared anyway was not failing at anything.

Individual foods still move in the expected directions

Two things are true at once.

The same analysis listed foods linked to higher serum urate: beer, liquor, wine, potato, poultry, soft drinks, and meat, meaning beef, pork or lamb. It also listed foods linked to lower serum urate: eggs, peanuts, cold cereal, skim milk, cheese, brown bread, margarine, and non-citrus fruits.

Long-term studies agree on direction. One followed 47,150 men with no history of gout for 12 years. It logged 730 new cases. A relative risk of 1.41 means the risk is 41 percent higher than in the comparison group, not that the risk is 41 percent. Comparing the highest intake with the lowest, the relative risk was 1.41 for meat and 1.51 for seafood. Dairy went the other way, at 0.56.

Translate the meat figure. About 5 in 100 US men have gout. A relative risk of 1.41 on that base lands near 7 in 100.

A second study followed 46,393 men and logged 755 new cases over 12 years. The base for comparison was less than one serving a month. Against that, five to six sugary soft drinks a week gave a relative risk of 1.29. One a day gave 1.45, and two or more a day gave 1.85. Across fifths of fructose intake, the values ran 1.00, 1.29, 1.41, 1.84 and 2.02. Diet soft drinks were not linked to gout risk.

One widely repeated rule did not survive testing. Purines are building blocks found in food and in the body, and they break down into urate. Purine-rich vegetables and total protein were not linked to higher gout risk.

Both studies enrolled male health workers. The numbers should not be moved across to women. A doctor or dietitian can say what they mean for one person.

How to hold both facts

• Diet shifts serum urate by a small amount in the general population
• Specific items still move risk in the expected direction, especially alcohol and sugar-sweetened drinks
• Family history and inherited variation account for far more of the difference between people
• Diet change alone will rarely bring gout to target, which is a talk to have with a doctor

Section recap: Diet scores explained no more than 0.3 percent of serum urate variance against 23.9 percent for common genetic variation. Individual foods still matter modestly, and the stigma is not proportionate to the evidence.

How much risk you are actually carrying: family history, heritability and absolute numbers

Relative risks feel bigger than they are. This section turns them into plain counts.

The baselines

Population figure	Value	Source
US adults with gout	3.9% (about 9.2 million)	NHANES 2015-2016
US men with gout	5.2% (about 5.9 million)	NHANES 2015-2016
US women with gout	2.7% (about 3.3 million)	NHANES 2015-2016
British Columbia, Canada, 2012	3.8% overall; over 8% at ages 60-69	Population-based BC data
People with European ancestry	3 to 4%	MedlinePlus Genetics
People with Asian ancestry	1%	MedlinePlus Genetics
Indigenous Taiwanese peoples and Maori from New Zealand	6 to 8%	MedlinePlus Genetics

The Canadian figure covers British Columbia, not the whole country. Gout became both more common and more frequent there from 2000 to 2012.

What family history is worth

A national study in Taiwan looked at records for 22,643,748 people. Of those, 1,045,059 had gout diagnosed by a doctor. It gives the most exact family figures available.

Affected relative	Relative risk of gout	95% confidence interval
Twin	8.02	6.95 to 9.26
Sibling	2.59	2.54 to 2.63
Offspring	1.96	1.95 to 1.97
Parent	1.93	1.91 to 1.94
Grandchild	1.48	1.43 to 1.53
Nephew or niece	1.40	1.32 to 1.47
Uncle or aunt	1.31	1.24 to 1.39
Grandparent	1.26	1.21 to 1.30

Any affected first-degree relative carried a relative risk of 1.91 in men and 1.97 in women. For second-degree relatives it was 1.27 in men and 1.40 in women.

Now the math, out loud. A US base of about 5 in 100 men, times 1.91, lands near 10 in 100. A father with gout roughly doubles a son’s risk. It also leaves about 90 of 100 such men who never get it.

That study was done in Taiwan, so its raw rates do not carry over to US or Canadian readers. The family pattern still does. A doctor can weigh it against one person’s own history.

Heritability, stated correctly

The same study split the causes, and the result differs by sex. Heritability means the share of the difference between people that genes explain. In men, genes accounted for 35.1 percent, shared surroundings 28.1 percent and other factors 36.8 percent. In women, the figures were 17.0 percent, 18.5 percent and 64.5 percent. The authors called the split sexually dimorphic, meaning different in men and women.

A single “gout is about 35 percent genetic” line is therefore wrong for women. The men-only figure is roughly twice the women-only figure.

Why there is no Punnett square here

Readers who have seen a carrier test expect a clean fraction. A carrier is a person who holds one changed copy of a single gene. Gout has no carrier state, so it produces no such fraction. The NIH gene guide states that the inheritance pattern of gout is unclear. Many genes and outside factors appear to be involved, though a close relative with gout likely raises risk.

There is no 25 percent figure here and no 50 percent figure. A doctor or a board-certified genetic counselor can explain why that differs from single-gene conditions.

Section recap: A first-degree relative with gout roughly doubles risk, moving a US man from about 5 in 100 to about 10 in 100. Heritability was 35.1 percent in men and 17.0 percent in women, not one shared number.

When gout is not polygenic: early-onset gout plus kidney disease in the family

Most family clustering of gout is polygenic. A small share is not. That small share is the one place where a genetic diagnosis changes what happens next.

Autosomal dominant tubulointerstitial kidney disease

A consensus report from the global kidney group KDIGO put several rare conditions under one name. It is called autosomal dominant tubulointerstitial kidney disease, or ADTKD. It is caused by changes in four genes: UMOD, HNF1B, REN and MUC1.

Older labels overlap directly with gout. They include “Familial Juvenile Hyperuricemic Nephropathy” and “Medullary Cystic Kidney Disease type 2”. A family given any of those labels may have had the same thing.

The UMOD form is the best studied. It is inherited in an autosomal dominant manner, meaning one altered copy is enough to cause it. Each child of an affected person has a 50 percent chance of inheriting the variant. Gout appears in the teenage years in about 8 percent of affected people. It develops in 55 percent over time, with a median onset near age 28. Kidney disease usually reaches kidney failure between the third and seventh decades of life.

The signs are quiet rather than dramatic. A urine test looks normal while kidney disease worsens slowly. That pairing is what sets it apart from other kidney diseases. A diagnosis needs gene testing ordered by a doctor. Sequencing finds over 95 percent of the harmful variants. A consumer DNA chip does not do this.

X-linked purine-salvage disorders

A second rare group involves the recycling of purines. Changes in the HPRT1 gene give three forms. Lesch-Nyhan disease sits at the severe end, with enzyme activity below 2 percent. A middle form runs from 2 to 8 percent. The mildest form, also called Kelley-Seegmiller syndrome, sits above 10 percent.

All three make too much uric acid from birth. That can show up as a high urate level, kidney stones and gout. They are X-linked, meaning the gene sits on the X chromosome. Males who inherit the variant will be affected. Females who inherit one copy are almost always well.

Changes in the PRPS1 gene make one enzyme overactive. It cannot be switched off, so the cell makes too many purines. The extra uric acid can cause kidney stones, bladder stones and gout. PRPS1 also sits on the X chromosome.

The red-flag checklist to hold against a family tree

• A first gout attack in the teens or twenties
• Gout appearing with declining kidney function across two or more generations
• A normal urinalysis alongside slowly worsening kidney function and a strong family history
• Urate kidney stones in adolescence, especially in a male

None of these confirm anything on their own. They are reasons to ask a doctor for a kidney or genetics referral, rather than to assume the common form.

That referral is the one situation in gout where genetic counseling clearly fits. Genetic counseling is a session with a trained specialist who explains what a test can and cannot show. In the US and Canada, board-certified counselors can be found through the National Society of Genetic Counselors directory. It covers over 3,300 members, in person or by video. Canadian readers can also use the national clinic list from the Canadian Association of Genetic Counsellors. A polygenic gout score on its own is not a reason for a referral.

Section recap: Early gout with kidney failure across generations can signal ADTKD (UMOD, HNF1B, REN, MUC1) or an X-linked purine-salvage disorder. Confirming either requires clinician-ordered diagnostic sequencing, not a consumer kit.

Treat-to-target: what the 2020 guideline says, and every drug’s regulator and date

Genetics explains the risk. Treatment is where outcomes change. The current US guideline for joint specialists is unusually specific.

The 2020 American College of Rheumatology guideline

The guideline gives 42 recommendations, 16 of them strong. These are the ones a reader should know.

• Target: for all patients taking urate-lowering therapy, the guideline strongly recommends continuing treatment to reach and maintain a serum urate below 6 mg/dL
• First-line drug: allopurinol is preferred, including for people with moderate-to-severe chronic kidney disease at stage 3 or beyond
• Starting dose: low, at 100 mg a day or less, and lower in kidney disease, then raised step by step using repeat urate tests
• Flare cover: keep it up for three to six months, not less, when starting urate-lowering therapy
• When to start: strong reasons include tophi, meaning lumps of urate crystals under the skin, joint damage seen on X-ray, or frequent flares
• High urate with no symptoms: above 6.8 mg/dL with no past flares or tophi, the guideline advises against starting any drug
• Acute flares: colchicine, non-steroidal anti-inflammatory drugs, or glucocorticoids are strongly recommended

Ask a doctor to write down the target number and the plan for rechecking it.

The one genetic test the guideline endorses

The guideline conditionally recommends testing HLA-B*5801 before starting allopurinol in patients of Southeast Asian descent, naming Han Chinese, Korean and Thai, and in African American patients. It conditionally recommends against that test in everyone else.

This is a clinical drug-safety gene test, ordered by a doctor. It does not come from a consumer DNA chip. It is the one gene test in gout care that a guideline backs.

A second gene issue sits on a drug label rather than in the guideline. The pegloticase label tells doctors to screen for G6PD deficiency, an inherited enzyme shortage that can make red blood cells break apart, before use.

Regulator-by-regulator status, with dates

What is sold in Canada never follows from US approval. Each product below was checked in both databases.

Drug	United States (FDA)	Canada (Health Canada)
Allopurinol	Long-established generic; guideline first-line	Marketed generics available
Febuxostat	Uloric approved 2009-02-13 (NDA 021856); boxed warning and narrowed indication via supplement approved 2019-02-21	Brand Uloric cancelled post market 2021-12-31; generic 80 mg products marketed, including one authorised since 2019-11-28
Pegloticase (Krystexxa)	Approved 2010-09-14 (BLA 125293); methotrexate co-administration label update approved 2022-07-07	No pegloticase product appears in the Drug Product Database as of 2026-08-28
Lesinurad (Zurampic)	Approved 2015-12-22; marketing status discontinued	No record in the Drug Product Database
Lesinurad with allopurinol (Duzallo)	Approved 2017-08-18; marketing status discontinued	No record in the Drug Product Database
AR882 (investigational)	Not approved; in phase 3	Not approved; no database record

The febuxostat story, told honestly

A trial of 6,190 patients compared febuxostat with allopurinol. All had gout and known heart disease. A hazard ratio compares how fast events pile up in two groups, and 1.00 means the same rate. The main outcome showed no difference, at a hazard ratio of 1.03. Two side results did differ. Death from any cause came in at 1.22, and heart-related death at 1.34.

The FDA acted on those findings. The current label carries a boxed warning headed “CARDIOVASCULAR DEATH”. It limits use to patients who did not respond to a fully raised allopurinol dose. It also covers those who cannot tolerate allopurinol, or for whom it is not advisable. That action matches a supplement approved on 2019-02-21.

A later trial did not repeat the signal. It reported an adjusted hazard ratio of 0.85 for the main heart outcome. It found febuxostat no worse than allopurinol. The question is unsettled, and the FDA limit stays in force either way.

Pegloticase, and what it is for

Pegloticase is for long-standing gout in adults that other drugs have failed to control. The dose is 8 mg every two weeks by drip, with weekly methotrexate 15 mg by mouth. It may be used alone when methotrexate is unsuitable.

The label reports the reason for that pairing. Serum uric acid stayed below 6 mg/dL for at least 80 percent of month six in 71 of 100 patients on the combination. The figure was 20 of 52 on pegloticase alone. The drug carries a boxed warning for severe allergic and drip reactions. The warning also covers blood problems in people with G6PD deficiency.

Canadian readers should note one plain finding. No pegloticase product appears in the Health Canada Drug Product Database as of 2026-08-28. A pharmacist or doctor can confirm what is stocked locally.

What urate lowering does not do

Three trials tested urate lowering as organ protection rather than as gout treatment.

• Heart disease: allopurinol made no difference to the main heart outcome, at a hazard ratio of 1.04
• Stage 3 to 4 kidney disease without gout: allopurinol did not slow the loss of kidney function, mean difference -0.10
• Type 1 diabetes: urate fell from 6.1 to 3.9 mg/dL, and kidney function showed no gain, difference 0.001

Two of those trials did not enroll people with gout, so they say nothing against treating gout. The fair reading is simple. Urate-lowering therapy earns its place by controlling gout, not by protecting the kidneys or the heart. A doctor can explain which reason applies to one patient.

What is not available yet

AR882 is a urate-lowering drug still in phase 3 testing, known as a URAT1 inhibitor after the urate transporter it blocks. One phase 3 study enrolling 750 people started on 2025-03-11 and is active but not recruiting. Its primary outcome measurement is scheduled to complete in September 2026. A second phase 3 study is complete. There is no approved product in the US or Canada.

The sponsor announced in August 2024 that the FDA granted Fast Track status for visible tophi. That is a company statement rather than a database record. Fast Track is not approval, and it is not evidence of benefit. A joint specialist can say what is actually available now.

A treatment gap is worth naming here. Only about 33 percent of US patients with gout were using urate-lowering therapy in 2007-2014, and about 22 percent in the British Columbia data. Whether a given reader belongs in that group is a question for their own physician.

Section recap: The 2020 guideline sets a serum urate target below 6 mg/dL with allopurinol first-line. Febuxostat carries a US boxed warning from 2019-02-21, and no pegloticase product is listed in Canada as of 2026-08-28.

Family, insurance and privacy in the US and Canada

The last set of questions is rarely medical. It concerns relatives, employers and insurers.

There is no cascade testing for gout

Cascade testing means offering the same gene test to relatives after one family member tests positive. That model fits single-gene conditions. It does not fit gout, because there is no single variant to trace.

What a brother or an adult child needs instead is a normal check-up. Gout travels with other conditions. In the British Columbia data, by 2012, 72 percent of people with gout also had high blood pressure. High cholesterol reached 52 percent and diabetes 18 percent. The NIH arthritis institute also lists kidney disease, high blood pressure and obesity among gout risk factors.

The useful thing to pass to relatives is the family history itself, not a percentage. Their own doctor decides which blood tests follow. The exception is the red-flag pattern above, where a genetics referral is the right ask.

US rules: what GINA covers and what it does not

• Health insurers may not use genetic information to set coverage or premiums
• Employers may not use genetic information in hiring, firing, promotion, pay or job assignment
• GINA does not apply to employers with fewer than 15 employees
• GINA’s health insurance protections do not cover long-term care insurance, life insurance, or disability insurance
• Some US states have passed their own rules for those categories

That fourth point matters to a reader shopping for life cover tied to a mortgage. It is exactly the gap GINA leaves.

One point prevents a common misreading. A diagnosed case of gout counts as a current condition, not as genetic information. These laws cover the consumer DNA result, not the diagnosis in a medical chart.

Canadian rules are broader

Canada’s Genetic Non-Discrimination Act was signed into law on 2017-05-04. Section 3(1) bars asking for a genetic test as a condition of goods or services. The same bar covers entering or keeping a contract, or setting its terms. Section 4(1) bars asking a person to hand over genetic test results for those same purposes. Section 5 bars collecting, using or sharing genetic test results without written consent.

Penalties are heavy. The most serious cases carry a fine up to $1,000,000 and up to five years in prison. Lesser cases carry up to $300,000 and 12 months. The Canadian law is therefore not limited to health cover and jobs.

Data custody can change hands

Consumer genetic data does not always stay with the company that collected it. 23andMe filed for Chapter 11 bankruptcy in March 2025. The court approved a sale to TTAM Research Institute, a nonprofit body, for $305 million. The company stated that the buyer “is committed to adhering to 23andMe’s existing privacy policies in perpetuity”. It added that customers would be emailed before closing, and could change their research participation choice.

Those are the company’s own words, not an outside guarantee. The practical step is to check the account settings for downloading data and for deleting an account.

On cost

Allopurinol is an old, cheap generic in both the US and Canada. Plan coverage was not checked for this article. Confirm it with an insurer, pharmacist or provincial plan rather than assuming it. A doctor or pharmacist can also say whether another named drug is stocked locally.

Section recap: There is no cascade genetic testing for gout, and relatives need clinical follow-up rather than a gene test. GINA excludes life, disability and long-term-care insurance, while Canada’s statute is broader.

Frequently asked questions

My uric acid is high. Will I get gout?

Probably not, on the numbers, though the risk is real and climbs with the level. About 20 in 100 US adults have a high urate level, while about 4 in 100 have gout. The NIH gene guide says about one-quarter of people with a high level go on to develop gout.

In an older male group, 4.9 percent had a first attack each year at 9 mg/dL or above. The rate was 0.5 percent at 7.0 to 8.9 mg/dL. The current US guideline advises against starting drugs when there are no symptoms. A doctor can weigh one level against one history.

Will my children inherit it?

Not the way a single-gene condition is passed on. Gout has no carrier state, and no fixed percentage, because many genes and outside factors are involved.

What the data give is a relative risk. A child of an affected parent carried a relative risk of 1.93 in the Taiwan study, with a 95 percent confidence interval of 1.91 to 1.94. On a US base of about 5 in 100 men, that lands near 10 in 100. The exception is the rare family pattern of early gout with kidney failure, which needs a doctor-ordered work-up.

Will this affect my health or life insurance?

For US health cover, genetic information cannot be used to set coverage or premiums. For life, disability and long-term-care cover, GINA does not apply, though some states add their own rules. Once gout is diagnosed it counts as a current condition, not as genetic information, so GINA is not the rule that governs it. In Canada, asking for a genetic test or its results as a condition of a contract is barred outright. Penalties reach a $1,000,000 fine and five years in prison. Anything tied to one policy is a question for a licensed insurance agent, and any medical detail should come from a doctor.

Can my employer find out?

Not lawfully in most US workplaces. Employers may not use genetic information in hiring, firing, promotion, pay or job duties. The rule does not reach employers with fewer than 15 staff. In Canada, the ban covers anyone offering goods, services or contracts. It also bars collecting, using or sharing genetic test results without written consent. A reader worried about one workplace should seek legal advice, and any medical note should come from their own doctor.

Should I get a second opinion?

For a consumer polygenic result, the useful next step is not another gene test. It is a serum urate test and a talk with a family doctor or a joint specialist. Gout is diagnosed in the clinic, not by a research score. A second opinion is worth seeking in two situations. The first is a family pattern matching the ADTKD or purine-salvage red flags, which calls for clinical genetics input. The second is a first allopurinol prescription in a person of Southeast Asian or African American background, where the guideline conditionally recommends HLA-B*5801 testing.

Section recap: The common questions have concrete answers, and most of them route to a serum urate test and a physician rather than to another genetic test.

Summary

Gout is two inherited systems failing together, not one bad habit. The first is urate handling, which runs through transporter genes such as ABCG2 and SLC2A9. The second is the immune reaction to crystals, which runs through the NLRP3 inflammasome.

The size of the genetic share is now well mapped. A 2024 study of 2.6 million people, including 120,295 with gout, found 377 loci and 410 independent signals. Of those loci, 149 had not been reported before. Its ranking work pointed at inflammatory genes, so inherited variation shapes the reaction and not only the urate level.

The numbers a reader can act on are these. About 20 in 100 US adults have hyperuricemia and about 4 in 100 have gout. A first-degree relative with gout roughly doubles risk, moving a US man from about 5 in 100 to about 10 in 100. Heritability was 35.1 percent in men and 17.0 percent in women, so the single figure often quoted is wrong for half of readers. Diet scores explained no more than 0.3 percent of serum urate variance, against 23.9 percent for common genetic variation.

Two escalations are worth carrying into an appointment. Early-onset gout alongside kidney failure across generations can indicate ADTKD, caused by variants in UMOD, HNF1B, REN or MUC1, or an X-linked purine-salvage disorder. And before a first allopurinol prescription, patients of Southeast Asian descent and African American patients are conditionally recommended for HLA-B*5801 testing.

The treatment target is a specific number: a serum urate below 6 mg/dL, reached by raising allopurinol step by step from a low starting dose. Regulatory status differs by country, and febuxostat is the worked example. The US brand carries a boxed warning from a 2019-02-21 action. The Canadian brand was cancelled post market on 2021-12-31, while generic febuxostat is marketed in both countries. No pegloticase product appears in the Health Canada database as of 2026-08-28.

The next step is not another search result. It is a serum urate level, a family history written down, and a physician who can read both.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Major TJ, Takei R, Matsuo H, Leask MP, Sumpter NA, Topless RK, et al. (2024). A genome-wide association analysis reveals new pathogenic pathways in gout. Nature Genetics 56(11):2392-2406 (epub 15 October 2024). PMID 39406924. DOI 10.1038/s41588-024-01921-5. https://pubmed.ncbi.nlm.nih.gov/39406924/
2. Major TJ, Topless RK, Dalbeth N, Merriman TR (2018). Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ 363:k3951. PMID 30305269. DOI 10.1136/bmj.k3951. Full text PMC6174725. https://pubmed.ncbi.nlm.nih.gov/30305269/
3. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237-241. PMID 16407889. DOI 10.1038/nature04516. https://pubmed.ncbi.nlm.nih.gov/16407889/
4. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK (2019). Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: NHANES 2007-2016. Arthritis & Rheumatology 71(6):991-999. PMID 30618180. DOI 10.1002/art.40807. With Rai SK, Avina-Zubieta JA, McCormick N, et al. (2017). The rising prevalence and incidence of gout in British Columbia, Canada. Seminars in Arthritis and Rheumatism 46(4):451-456. PMID 28040245. https://pubmed.ncbi.nlm.nih.gov/30618180/
5. Campion EW, Glynn RJ, DeLabry LO (1987). Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. American Journal of Medicine 82(3):421-426. PMID 3826098. DOI 10.1016/0002-9343(87)90441-4. https://pubmed.ncbi.nlm.nih.gov/3826098/
6. Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M (2009). Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. PNAS 106(25):10338-10342. PMID 19506252. DOI 10.1073/pnas.0901249106. Full text PMC2700910. https://pubmed.ncbi.nlm.nih.gov/19506252/
7. Lv X, Zhang Y, Zeng F, et al. (2014). The association between the polymorphism rs2231142 in the ABCG2 gene and gout risk: a meta-analysis. Clinical Rheumatology 33(12):1801-1805. PMID 24777469. DOI 10.1007/s10067-014-2635-x. https://pubmed.ncbi.nlm.nih.gov/24777469/
8. Vitart V, Rudan I, Hayward C, et al. (2008). SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nature Genetics 40(4):437-442. PMID 18327257. DOI 10.1038/ng.106. With Doring A, Gieger C, Mehta D, et al. (2008). SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nature Genetics 40(4):430-436. PMID 18327256. DOI 10.1038/ng.107. https://pubmed.ncbi.nlm.nih.gov/18327257/
9. Kuo CF, Grainge MJ, See LC, Yu KH, Luo SF, Valdes AM, Zhang W, Doherty M (2015). Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in Taiwan. Annals of the Rheumatic Diseases 74(2):369-374. PMID 24265412. DOI 10.1136/annrheumdis-2013-204067. Full text PMC4316854. https://pubmed.ncbi.nlm.nih.gov/24265412/
10. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ (2019). Clinical use of current polygenic risk scores may exacerbate health disparities. Nature Genetics 51(4):584-591. PMID 30926966. DOI 10.1038/s41588-019-0379-x. Full text PMC6563838. https://pubmed.ncbi.nlm.nih.gov/30926966/
11. FitzGerald JD, Dalbeth N, Mikuls T, et al. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research 72(6):744-760. PMID 32391934. DOI 10.1002/acr.24180. Full text PMC10563586. https://pmc.ncbi.nlm.nih.gov/articles/PMC10563586/
12. White WB, Saag KG, Becker MA, et al. (2018). Cardiovascular safety of febuxostat or allopurinol in patients with gout (CARES). New England Journal of Medicine 378(13):1200-1210. PMID 29527974. DOI 10.1056/NEJMoa1710895. With Mackenzie IS, Ford I, Nuki G, et al. (2020). Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST). Lancet 396(10264):1745-1757. PMID 33181081. DOI 10.1016/S0140-6736(20)32234-0. https://pubmed.ncbi.nlm.nih.gov/29527974/
13. Mackenzie IS, Hawkey CJ, Ford I, et al. (2022). Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART). Lancet 400(10359):1195-1205. PMID 36216006. With Badve SV, Pascoe EM, Tiku A, et al. (2020). Effects of allopurinol on the progression of chronic kidney disease (CKD-FIX). New England Journal of Medicine 382(26):2504-2513. PMID 32579811. And Doria A, Galecki AT, Spino C, et al. (2020). Serum urate lowering with allopurinol and kidney function in type 1 diabetes (PERL). New England Journal of Medicine 382(26):2493-2503. PMID 32579810. https://pubmed.ncbi.nlm.nih.gov/36216006/
14. US Food and Drug Administration. Drugs@FDA application records and current prescribing information, retrieved via the openFDA drug/drugsfda and drug/label APIs on 2026-08-28. Febuxostat NDA 021856 approved 2009-02-13, supplement 13 approved 2019-02-21; pegloticase BLA 125293 approved 2010-09-14, supplement 104 approved 2022-07-07; lesinurad NDA 207988 approved 2015-12-22 and NDA 209203 approved 2017-08-18, both discontinued. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021856
15. Health Canada Drug Product Database, queried via the health-products.canada.ca API on 2026-08-28. Uloric DIN 02357380 cancelled post market 2021-12-31; generic febuxostat 80 mg products marketed including DIN 02466198 since 2019-11-28; no pegloticase and no lesinurad records under any status code; allopurinol generics marketed. https://health-products.canada.ca/dpd-bdpp/search/
16. GeneReviews, NCBI Bookshelf (National Library of Medicine, NIH). Autosomal Dominant Tubulointerstitial Kidney Disease – UMOD; with MedlinePlus Genetics UMOD gene entry. Retrieved live 2026-08-28. https://www.ncbi.nlm.nih.gov/books/NBK1356/
17. Eckardt KU, Alper SL, Antignac C, et al.; Kidney Disease: Improving Global Outcomes (2015). Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management – A KDIGO consensus report. Kidney International 88(4):676-683. PMID 25738250. DOI 10.1038/ki.2015.28. https://pubmed.ncbi.nlm.nih.gov/25738250/
18. GeneReviews, NCBI Bookshelf (National Library of Medicine, NIH). HPRT1 Disorders; with MedlinePlus Genetics entries for HPRT1 and PRPS1. Retrieved live 2026-08-28. https://www.ncbi.nlm.nih.gov/books/NBK1149/
19. MedlinePlus Genetics (National Library of Medicine, NIH), “Gout”; and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH), “Gout”. Both retrieved live 2026-08-28. https://medlineplus.gov/genetics/condition/gout/
20. National Human Genome Research Institute (NIH), Genetic Discrimination and the Genetic Information Nondiscrimination Act of 2008; and Genetic Non-Discrimination Act, S.C. 2017, c. 3, Justice Laws Website, Government of Canada. Both retrieved live 2026-08-28. https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
21. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004). Purine-rich foods, dairy and protein intake, and the risk of gout in men. New England Journal of Medicine 350(11):1093-1103. PMID 15014182. DOI 10.1056/NEJMoa035700. With Choi HK, Curhan G (2008). Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 336(7639):309-312. PMID 18244959. DOI 10.1136/bmj.39449.819271.BE. https://pubmed.ncbi.nlm.nih.gov/15014182/
22. ClinicalTrials.gov (National Library of Medicine, NIH), registry records for AR882 (Arthrosi Therapeutics), including NCT06846515 and NCT06439602, queried via the official API on 2026-08-28; cross-checked against Drugs@FDA via openFDA and the Health Canada Drug Product Database. https://clinicaltrials.gov/study/NCT06846515
23. National Society of Genetic Counselors, Find a Genetic Counselor directory; and the Canadian Association of Genetic Counsellors national clinic directory. Both retrieved live 2026-08-28. https://findageneticcounselor.nsgc.org/
24. 23andMe clinician-facing Health Predispositions reference page and the 23andMe press release on the TTAM Research Institute sale dated 2025-06-30 (company product documentation, cited only for the company’s statements about its own product and corporate status). Retrieved live 2026-08-28. https://www.23andme.org/clinicians/genetic-reports/health-predispositions/

Last updated: 2026-08-28

Author: Yu Mizuno (Editor-in-Chief, non-physician), GeneLumen editorial team. This article aggregates 24 sources from peer-reviewed medical literature and public health agencies (tier 1=19 / tier 2=4 / tier 4=1), including NIH resources (MedlinePlus Genetics, NIAMS, GeneReviews, NHGRI, ClinicalTrials.gov), the American College of Rheumatology guideline, the KDIGO consensus report, the FDA and Health Canada drug databases, Canadian federal statute, and PubMed-indexed publications. Editorial lead: Yu Mizuno, a non-physician research editor.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada).

Related: Metabolic and Hematologic Genetic Diseases category

🌐 日本語版: 痛風は遺伝するのか｜260万人GWASとABCG2が覆した「ぜいたく病」という誤解